Compound profile
CJC-1295
Also known as CJC-1295 with DAC, Modified GRF (1-29)
Last reviewed October 2026
Educational only. A summary of published research, not medical advice or a recommendation. No doses are listed.
Quick take
A synthetic GHRH analogue designed to last much longer than the body's own GHRH.
- Class
- Growth hormone secretagogues
- Status
- Not approved
- Evidence
- Early or small human studies
- Half-life
- About 6–8 days with DAC; about 30 minutes without
Mechanism fingerprint
What it acts on, and how. Each chip links to that pathway on the map.
Stimulates growth hormone release. The “DAC” version binds albumin in the blood, which greatly extends how long it lasts; versions without DAC (often sold as modified GRF 1-29) are short-acting.
What makes it different
A GHRH analogue engineered to last longer: the DAC version binds albumin and lasts days, while versions without DAC last minutes.
Compare side by side
Mechanism & pathways
-
Agonist
GHRH receptor
in the pituitary
Receptor in the pituitary gland for growth hormone–releasing hormone (GHRH). Activating it releases the body's own growth hormone in pulses.
Leads to Growth hormone & GH receptor IGF-1
Evidence overview
Early or small human studies
Small early-phase studies in healthy adults showed sustained increases in growth hormone and IGF-1.
A breakdown into human, animal and cell studies hasn't been added for this compound yet.
Why it's used
Used to raise growth hormone and IGF-1 for longer than the body's own GHRH does; sold online as a research chemical.
Side effects & risks
Reported side effects
- Injection-site reactions
- Flushing
- Headache
Risks and warnings
- Long-term safety unknown
- Prohibited in sport by the World Anti-Doping Agency (WADA).
- Products sold as “research use only” are not quality-controlled medicines; purity, sterility and labeled amount are not verified.
FAQ
Short answers taken from this profile.
What is CJC-1295?
A synthetic GHRH analogue designed to last much longer than the body's own GHRH.
How does CJC-1295 work?
Stimulates growth hormone release. The “DAC” version binds albumin in the blood, which greatly extends how long it lasts; versions without DAC (often sold as modified GRF 1-29) are short-acting.
What receptors or pathways does CJC-1295 act on?
GHRH receptor (agonist; in the pituitary). Downstream, that leads to growth hormone & GH receptor and IGF-1.
How is CJC-1295 different from similar compounds?
A GHRH analogue engineered to last longer: the DAC version binds albumin and lasts days, while versions without DAC last minutes.
What is the half-life of CJC-1295?
About 6–8 days with DAC; about 30 minutes without.
Is CJC-1295 approved?
Not approved. Early clinical development was discontinued.
What has CJC-1295 been studied for?
Used to raise growth hormone and IGF-1 for longer than the body's own GHRH does; sold online as a research chemical.
How strong is the evidence?
Early or small human studies. Small early-phase studies in healthy adults showed sustained increases in growth hormone and IGF-1.
What are the main risks?
Long-term safety unknown. Prohibited in sport by the World Anti-Doping Agency (WADA). Products sold as “research use only” are not quality-controlled medicines; purity, sterility and labeled amount are not verified.
Sources
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006.